Biohacking Kompakt

Podcast episode 158 (in German)

Update: Testosterone – the belly counts more than age

November 15, 2026

The US Food and Drug Administration wants to soften the warnings on testosterone, and on social media the trend is called "T-maxxing". The episode shows why neither is a free pass and why waist size says more about testosterone than age.

What it is about

The second Sunday update: what has happened since episode 22 in July? The big figure from back then still stands, the heart data from the TRAVERSE trial. New are the FDA request for softer warnings, an analysis of how much age and belly fat account for testosterone, the first randomised trial after prostate cancer and data on the prescription boom among younger men. Paul also corrects two statements from the July episode.

Key points

  • In June 2026 the FDA asked manufacturers to change the package inserts: the sentence saying the benefit in age-related deficiency is not established is to be removed, and prostate cancer is to be a contraindication only when it has spread. This has been requested but, as far as we can find, not yet implemented. In Germany testosterone remains prescription-only and approved for medically confirmed deficiency.
  • In almost 5,000 US men aged 20 to 59, age explains 2.5 percent of the differences in testosterone, waist size 18 to 20 percent. According to a JAMA review, deficiency due to disease of the testes or pituitary affects fewer than 1 percent of men, deficiency linked to marked overweight 2 to 8 percent; there, weight loss is the first choice.
  • Two corrections to the July episode: in the TRAVERSE substudy of men with low desire, desire and sexual activity rose over two years, but erectile function did not improve. Bone density rises, but no study shows fewer fractures; in TRAVERSE there were even more, 3.5 versus just under 2.5 percent.
  • What holds up: small but real improvements in mood and energy. Anaemia had resolved after six months in 41 percent, on placebo in 27.5 percent, and in men over 60 lean mass grows by 1.6 to 3.6 kilograms.
  • The first randomised trial after prostate cancer (JAMA Internal Medicine, July 2026): 136 men whose prostate had been removed for low-risk cancer and whose PSA had been undetectable for at least two years received testosterone or placebo for twelve weeks. There was no PSA recurrence in either group, and desire and sexual activity rose.
  • In Germany, prescriptions among 20- to 29-year-olds rose by 118 percent from 2009 to 2021, and about a third of first prescriptions carried no diagnosis matching the approval (insurance data on about 25 million people, commissioned by the BfArM). In a Lübeck analysis of more than 350,000 men starting testosterone, a good third had no sign of deficiency; in this group major cardiovascular events occurred in 16.5 versus just under 12 percent, and the risk of death was almost twice as high.
  • In the BK-Score the hype gap falls from 4 to 3 because marketing is running ahead of the evidence; human evidence and safety data stay at 9.

Chapters (episode in German)

  1. 0:00T-maxxing and a softer FDA
  2. 0:39What testosterone does and what has held since July
  3. 1:35The FDA: requested, not implemented
  4. 2:55The belly counts more than age
  5. 4:02Deficiency after earlier androgen use
  6. 4:39Two corrections: desire, erections and bones
  7. 5:41What holds up: mood, anaemia, lean mass
  8. 6:35The first trial after prostate cancer
  9. 7:32The prescription boom among younger men
  10. 8:39Lübeck: the diagnosis condition
  11. 9:38BK-Score and conclusion

Where the data stop

The Lübeck figures come from an observational study. The groups may have differed in many ways, so harm is not proven. But they show that the reassuring TRAVERSE data apply to men with confirmed deficiency, not automatically to everyone else. Even for them a signal remains: slightly more atrial fibrillation, 3.5 versus 2.4 percent.

The prostate cancer trial ran for twelve weeks and applies only to this form after surgery; it says nothing about long-term safety. In an Australian clinic, almost a third of just under 300 men referred for testosterone deficiency had previously used androgens; whether the deficiency was the consequence is not stated in the paper.

The path to a diagnosis remains the same: take symptoms seriously, have testosterone measured at least twice in the fasting state in the morning, and take an honest look at the belly first. Diagnosis and monitoring belong in medical hands.

Listen (in German)

Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music

Published on November 15, 2026.

The topic in the database

  • The central male sex hormone and replacement therapy for medically confirmed deficiencyTestosterone & TRT

More episodes

All episodes in the app (German)

Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-11-15.